Landi D. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Abstract 338. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Ontregel het onderzoek
dec 2022
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen